Highest-materiality recent filing
Bausch + Lomb closes $2.8B term loan refinancing, reduces margins, extends maturity
Closed $2.802B Replacement Term Loans maturing 2031 to refinance existing term B loans due 2028 and 2031.
Issued $1.6B aggregate principal of new 10.00% Senior Secured Notes due 2032 in exchange for outstanding 4.875% and 11.00% notes due 2028.
Bausch Health completes debt exchange for up to $1.6B in 10.00% senior secured notes due 2032
Exchange offers expired Dec. 23, 2025; old 4.875% and 11.00% senior secured notes due 2028 exchanged for new notes.
Bausch + Lomb refinances $2.8B term loans; margin cut, maturity extended to 2031
$2.802B new Replacement Term Loans to refinance existing term B loans due 2028 and 2031.
Bausch Health launches exchange of up to $1.6B notes, offers 10% senior secured notes due 2032
Offers to exchange 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032; up to $1.6B aggregate principal.
Bausch Health completes acquisition of DURECT for $1.75/share plus CVRs
Tender offer closed with 62% of DURECT shares (19.98M) validly tendered and accepted.
Brett M. Icahn and Steven D. Miller resigned from the board effective August 14, 2025, upon termination of the Director Appointment and Nomination Agreement.
Bausch Health to acquire DURECT for $1.75/share ($63M upfront) plus up to $350M milestones
Bausch Health will pay $1.75/share cash upfront, valuing DURECT at ~$63M, with up to $350M in additional net sales milestone payments.
Bausch + Lomb closes upsized €675M senior secured notes and $2.325B term loan refinancing
Issued €675M senior secured floating rate notes due 2031 at 3-month EURIBOR+3.875%.
Bausch + Lomb prices €675M secured notes, upsized; new term loan $2.325B
Priced €675M senior secured floating rate notes due 2031 at 99.5% of principal; offering upsized from €600M.
Bausch + Lomb launches €600M senior secured notes offering and $2.2B term loan refinancing
Subsidiaries launch €600M senior secured floating rate notes.
Bausch Health closes $4.4B 10% secured notes due 2032 and $3B term loan facility
Closed offering of $4.4B aggregate principal of 10.000% senior secured notes due 2032 via subsidiary 1261229 B.C. Ltd.
Bausch Health prices $4.4B 10% senior secured notes due 2032, upsized from $4.0B
Bausch Health priced $4.4B aggregate principal of 10.000% senior secured notes due 2032, upsized from $4.0B.
Bausch Health launches $4.0B secured notes offering and $3.8B credit facilities to refinance debt
Indirect subsidiary launched $4.0B senior secured notes due 2032 to qualified institutional investors.
Bausch + Lomb borrows $400M in new term loans maturing May 2027
Bausch + Lomb added $400M term loans under its credit agreement; proceeds used to repay revolver and for corporate purposes.
Bausch Health appoints Jean-Jacques Charhon as CFO, Aimee Lenar as EVP US Pharma
Jean-Jacques Charhon named CFO effective Aug 19, 2024; base salary $700K, target bonus 60%, equity grants ~$3M.
Bausch Health's B+L closes $1.75B acquisition of XIIDRA from Novartis; issues $1.9B in debt
Bausch + Lomb acquired XIIDRA and other ophthalmology assets from Novartis for $1.75B upfront cash plus up to $750M in milestone payments.
Bausch + Lomb completes $2.5B XIIDRA acquisition from Novartis, funded with $1.9B debt
Upfront $1.75B cash plus up to $750M milestone for XIIDRA and other ophthalmology assets from Novartis.
Bausch + Lomb subsidiary prices $1.4B 8.375% senior secured notes due 2028
Bausch + Lomb subsidiary Bausch + Lomb Escrow Corp. priced $1.4B of 8.375% senior secured notes due 2028.
Bausch + Lomb launches $1.4B notes offering and $500M term loan for XIIDRA acquisition
Bausch + Lomb Escrow Corp. launched $1.4B senior secured notes due 2028; Bausch + Lomb seeks $500M incremental term B loan.
Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets
Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.
On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
until a permanent replacement is in place, at the time that Mr. Barresi ceases to be the Chief Accounting Officer, Jean-Jacques Charhon, who is currently serving as the Company’s Executive Vice President and Chief Financial Officer, will assume the additional role of Chief Accounting Officer.
On May 9, 2025, John S. Barresi informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Senior Vice President, Controller and Chief Accounting Officer of the Company.
John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.
On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.
On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.
On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.
Tom Vadaketh informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Executive Vice President, Chief Financial Officer of the Company.
John S. Barresi, who is currently serving as the Company’s Senior Vice President, Controller and Chief Accounting Officer, will assume the additional role of interim Chief Financial Officer.
On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).
On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).
Also on June 23, 2022, the Company announced the Board’s appointment of John A. Paulson to the Board to fill the resulting vacancy, effective upon Mr. Papa’s resignation.
Max materiality 0.85 · Median 0.53 · Most common event debt